Heron (HRTX) Q2 Acute Care Jumps 56%

Heron Therapeutics (NASDAQ:HRTX), a biopharmaceutical company focused on acute care and oncology drugs, released its second quarter 2025 results on August 8, 2025. The standout news was a 55.5% jump in Acute Care segment revenue, offset by another GAAP revenue shortfall versus analyst expectations and continued weakness in the Oncology segment. Net revenue (GAAP) was $37.2 million, trailing the $38.075 million consensus and showing year-over-year growth of 3.3%. GAAP loss per share was $(0.02) versus an expectation of $(0.01), while operating losses narrowed and adjusted EBITDA (non-GAAP) turned positive year-over-year. The quarter showed progress, particularly in acute care, but ongoing Oncology declines and the GAAP revenue miss left a mixed overall impression. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Heron Therapeutics specializes in the development and commercialization of therapeutics for patients in acute care and oncology settings. Its portfolio includes pain management and anti-nausea drugs aimed at the hospital and outpatient care markets.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool